The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion

Inclusion criteria

• Men or women ≥ 18 years old;
• Acute occlusion of M1 or intracranial internal carotid artery within 72 hours;
• For patients who receive recombinant tissue-type plasminogenactivator therapy, the arterial occlusive lesion scale of 24-72 hours post-thrombolysis imaging should be 0 or 1;
• Ischemic stroke with National Institutes of Health Stroke Scale ≥ 4;
• Baseline mRS before this stroke onset less than 2;
• Able and willing to comply with study requirements;
• Signed informed consent by patients self or legally authorized representatives.

Exclusion criteria

• Cerebral hemorrhage;
• Posterior circulation infarction;
• Severe tendency of hemorrhage, such as thrombocytopenia, leukemia, allergic purpura;
• Currently using urinary kallidinogenase or alprostadil;
• Be allergic to NBP or celery;
• Impaired liver function (alanine aminotransferase or glutamic oxalacetic transaminase ≥ 3×upper limit of normal) or renal function (serum creatinie ≥ 1.5mg/dl);
• Patients with evidence of severe congestive heart failure or history of end-stage cardiovascular disease (e.g. congestive heart failure New York Heart Association Class III or IV);
• Metastatic neoplasm or multiple organ failure;
• Pregnancy or breastfeeding;
• History of mental instability or dementia.